Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q96C19
UPID:
EFHD2_HUMAN
Alternative names:
Swiprosin-1
Alternative UPACC:
Q96C19; Q5JYW9
Background:
EF-hand domain-containing protein D2, also known as Swiprosin-1, plays a crucial role in regulating B-cell receptor (BCR)-induced apoptosis in immature and primary B-cells. It acts as a negative regulator of the canonical NF-kappa-B-activating branch and controls spontaneous apoptosis by regulating BCL2L1 abundance.
Therapeutic significance:
Understanding the role of EF-hand domain-containing protein D2 could open doors to potential therapeutic strategies.